-
Redefining lymphoma treatment! Takeda Antibody Drug Coupling (ADC) Adcetris (Asili, Vibutusixim) has been officially approved by China!
Time of Update: 2020-05-16
2020 May 16 News / BioValley BIOON / - Takeda China recently announced that the Chinese State Drug Administration (NMPA) has formally approved the comfortable advantage ( English trade name: Adce
-
Caposi Sarcoma (KS): The only oral, first new drug in 20 years, Andher's Squibb Pomalyst (Pomalyst) is approved by the United States!
Time of Update: 2020-05-16
May 16, 2020 / PRNewswire BIOON/-BMS, Inc., announced that the U.S Food and Drug Administration ( FDA ) has approved Pomaliste (pomalidomide, Pomadodomide), a drug that has the activity of anti-
-
Redefining the first-line treatment of lymphoma! Takeda CD30 target drug Adcetris is approved by the European Union to treat inter-system largecell lymphoma (sALCL)!
Time of Update: 2020-05-15
2020 May 15 News / BioValley BIOON / - Takeda Pharmaceuticals (TakedaPharma) today announced that the European Commission (EC) has approved the expansion of Adcetris (brentuximabvedotin) conditio
-
China's first indication! Roche VENTANA PD-L1 (SP263) test approved as an accompanying diagnosis for urinary disease
Time of Update: 2020-05-15
2020 Nian 5 15, the world leader in in vitro diagnostics, Roche Diagnostics announced VENTANAPD-L1 (SP263) detection formally approved the listing in China The detection of the tumor microenvironmen
-
Odivo (Navuliyu monoantigen) combined with Ipitano monoantigen treatment metastasis non-small cell lung cancer three-year follow-up to obtain positive data, significantly prolonged the progression-free survival
Time of Update: 2020-05-14
2020 May 13, Bristol-Myers Squibb announced a 3-year follow-up results of a phase III clinical study CheckMate227 Part 1 The results showed that the United Iraqi Ou Diwo match adalimumab line treatm
-
Triple-negative breast cancer (TNBC) heavyweight! Mersadon Keytruda plus chemotherapy first-line treatment PD-L1 high expression patients significantly extended progressionless survival!
Time of Update: 2020-05-14
2020 May 14 News / BioValley BIOON / - Merck Sharp & Dohme (Merck & Co) recently announced the anti-PD-1 therapy Keytruda (can Rui up, common name: KEYNOTE-355 study pembrolizumab, Pabo Li natal
-
New myeloma drug! Sanofi CD38 Antibody Sarclisa Phase II Phase II trial pre-empts Johnson and Johnson's $3 billion drug Darzalex
Time of Update: 2020-05-13
2020 May 13 News / BioValley BIOON / - Sanofi (Sanofi) today announced that assess CD38 targeting antibody drug Sarclisa (isatuximab) treatment IKEMA a recurrence of clinical trials and / or ref
-
New treatment for ovarian cancer! Olapari and Bevalazumab combination therapy approved in the United States for HRD-positive advanced ovarian cancer patients first-line maintenance treatment
Time of Update: 2020-05-12
May 11, 2020, AstraZeneca and Mercado jointly announced that the jointly developed PARP inhibitor Liptro® (Name Lynparza, generic name: Olapari) has been approved by the U.S Food and Drug Administra
-
Nat Cell Biol: New immune cells found in the breast that can reshape the breast and prevent breast cancer!
Time of Update: 2020-05-12
May 12, 2020 / Biovalley BIOON/- Researchers in Melbourne's Breast Cancer have discovered a new type of immune cell that can help maintain the health of breast tissue by regulating an important p
-
HER2-positive stomach cancer first ADC drug! FDA grants AstraZeneca Enhertu breakthrough drug eligibility that will redefine stomach cancer treatment!
Time of Update: 2020-05-12
May 12, 2020 / Biovalley BIOON/ -- AstraZeneca and partner Daiichi Sankyo recently announced that the U.S Food and Drug Administration ( FDA ) has awarded HER2 Target Antibody Drug Conjugate (ADC
-
RET-driven cancer new treatment! Lilly Retevinib ™ has been approved by the U.S. FDA, becoming the first treatment for patients with advanced lung cancer and thyroid cancer with reT-driven genes
Time of Update: 2020-05-11
May 9, 2020, Lilly Pharmaceuticals (NYSE: LLY) announced that the U.S Food and Drug Administration (FDA) approved the Retevmo ™ (elpercatinib 40 mg, 80 mg capsule), the first approved specifically f
-
Nat Immunol: A New Breakthrough in Immunotherapy! Promising to improve cancer immunotherapy
Time of Update: 2020-05-11
May 11, 2020 / prnewswire BIOON / - Our immune system protects us not only from infection, but also from cancer This powerful protection is based on the activation of special cells of the immune sy
-
Domestic anti-PD-1 therapy! Junshi bio Trepri monoantigen (Tuyi ®) urinary disease (UC) new indications application by the State Drug Administration to accept!
Time of Update: 2020-05-10
May 10, 2020 / Biovalley BIOON / -- Junshi Bio recently announced that the State Drug Administration (NMPA) has accepted applications for new indications for treating patients with local progress
-
New immunotoxin! Vicinium treatment of high-risk BCG non-response bladder cancer (NMIBC) EU regulatory pathway clear, the United States into rolling review!
Time of Update: 2020-05-08
May 08, 2020 / BioValley BIO/ -- SeenBio is a late-stage, clinical biopharmaceutical company focused on developing targeted fusion protein therapies for cancer Recently, the company announced that
-
Change the tumor from "cold" to "hot"! Intra-tumor immunotherapy Tavo unlocks PD-1 checkpoint potential, combined With K drug treatment of drug-resistant melanoma efficacy is strong!
Time of Update: 2020-05-08
May 08 , 2020 /PRNewswire BIOON/ -- Oncoec Medical Medicaled is a biotech company focused on developing immunotherapy for tumors tumors in the tumor Recently, the company announced that it had ach
-
PNAS: Chinese scientists reveal new treatment for IDH1 mutant glioma!
Time of Update: 2020-05-08
May 8, 2020 / Biovalley BIOON / -- The findings of a new study led by Professor Xu Guowang of the Dalian Institute of Chemical Physics (DICP) of the Chinese Academy of Sciences have shed light o
-
"Screening love small station" landing nationwide, ovarian cancer patients full management system upgrade
Time of Update: 2020-05-08
May 8, 2020, on the occasion of the 8th World Ovarian Cancer Day, the national launch of the "Screening Love Station" project, jointly supported by AstraZeneca China and Mercado, was successfully la
-
HER2-positive stomach cancer first ADC drug! First three co-antibody drug conjugate (ADC) Enhertu in Japan to submit a new indication sin application!
Time of Update: 2020-05-08
08 May 2020 / Biovalley BIOON / -- Daiichi Sankyo recently announced that it has submitted a new drug supplementary application (ND) to Japan's Ministry of Health, Labour and Welfare (MHLW) A), se
-
Dabershu ® combine health-selected ® and platinum chemotherapy first-line treatment of squamous non-small cell lung cancer Phase III study obtained positive data, significantly prolonged the non-progressive survival!
Time of Update: 2020-05-07
May 7, 2020, Lilly Pharmaceuticals (NYSE: LLY) and Cinda Biopharma jointly announced: A randomized, double-blind, Phase III controlled clinical study (ORIENT-12) of the innovative PD-1 inhibitor Dam
-
Base cell carcinoma (BCC) immunotherapy! Sanofi/Regenerative Met anti-PD-1 therapy Libtayo is showing strong efficacy and will be submitted this year!
Time of Update: 2020-05-06
May 07, 2020 /prnewswire BIOON/ -- Sanofi and partner Regeneron recently released top-line data for a key single-arm open label Phase II clinical trial evaluating anti-PD-1 therapy Libtayo (BCC) t
